PURPOSE. Docosahexaenoic acid (DHA 22:6n3 ), the principal n3-polyunsaturated fatty acid (PUFA) in the retina, has been shown to have a pronounced anti-inflammatory effect in numerous in vivo and in vitro studies. Despite the importance of vascular inflammation in diabetic retinopathy, the anti-inflammatory role of DHA 22:6n3 in cytokine-stimulated human retinal vascular endothelial cells (hRVECs) has not been addressed. METHODS. Cytokine-induced expression of cell adhesion molecules (CAMs) was assessed by Western blot. The effect of DHA 22:6n3 on cytokine-induced nuclear factor (NF)-B signaling was analyzed by Western blot analysis and electrophoretic mobility shift assay (EMSA). RESULTS. Stimulation of hRVECs with VEGF 165 , TNF␣, or IL-1␤ for 6 to 24 hours caused significant induction of intracellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 expression. Pretreatment of the cells with 100 M of BSA-bound DHA 22:6n3 for 24 hours remarkably inhibited cytokine-induced CAM expression. IL-1␤, TNF␣, and VEGF 165 induced nuclear translocation and binding of p65 and p50 NF-B isoforms to the VCAM-1 promoter. DHA 22:6n3 pretreatment inhibited cytokine-induced NF-B binding by 25% to 40%. Moreover, DHA 22:6n3 diminished IL-1␤ induced phosphorylation of the inhibitor of nuclear factor (NF)-B (I-B␣), thus preventing its degradation. CONCLUSIONS. IL-1␤, TNF␣, and VEGF 165 induced CAM expression in hRVECs through activation of the NF-B pathway. DHA 22:6n3 inhibited cytokine induced CAM expression through suppression of NF-B nuclear translocation and upstream I-B␣ phosphorylation and degradation. DHA 22:6n3 could be an important anti-inflammatory agent in the face of increased cytokine production and CAM expression in the diabetic retina. (Invest Ophthalmol Vis Sci. 2005;46:4342-4347) 
T he early stage of diabetic retinopathy has been recognized to result from a chronic inflammatory condition involving attachment to and transmigration of leukocytes through the retinal microvasculature. [1] [2] [3] Several inflammatory pathways are active in the early stages of diabetic retinopathy. Proinflammatory cytokines including TNF␣ 4 -7 and IL-1␤ 8 are elevated in the extracellular matrix, endothelium, vessel walls, and vitreous of eyes of patients with proliferative diabetic retinopathy; and in the retinas of rats after 2 months of diabetes. Moreover, inhibition of TNF␣ and IL-1␤ signaling with a TNF␣ receptor/Fc construct 2 or with ILRa 9 significantly reduced leukocyte adhesion and endothelial cell (EC) injuries. Vascular endothelial cell growth factor (VEGF) has also been strongly implicated in the pathogenesis of both background and proliferative diabetic retinopathy. 10 -13 Increased intraocular VEGF levels, as well as VEGF receptor 1 and 2 were detected in the rat and human diabetic retina. 10 -18 In addition to its well-known mitogenic and angiogenic activity, VEGF was recently recognized as a proinflammatory cytokine. 19, 20 As such, VEGF induces intercellular adhesion molecule (ICAM)-1 expression on endothelial cells 19 and specific inhibition of the VEGF pathway inhibits ICAM-1 expression, leukocyte adhesion, blood-retinal barrier breakdown, and neovascularization in streptozotocin (STZ)-induced diabetic rats. 19 These data suggest an important role for TNF␣, IL-1␤, and VEGF (and their receptors) in the activation of signaling pathways leading to endothelium injury preceding the development of diabetic retinopathy. Despite these findings, the effect of inflammatory cytokines on human retinal endothelial cells has not been well studied.
Inflammatory cytokines function through their receptors, to initiate a series of signal transduction events that generally lead to the phosphorylation and degradation of inhibitor of nuclear factor (NF)-B (I-B) followed by the translocation and activation of NF-B in the nucleus. 21 NF-B is an important transcription factor controlling the expression of an array of inflammatory response genes including adhesion molecules. 21 Activation of NF-B (p65 and p50) has been well documented in diabetes, especially in the retinal vasculature of diabetic patients and in animal models. 19, 22 In vitro high glucose has been shown to cause the activation of NF-B in bovine retinal endothelial cells and pericytes. 22, 23 The role of NF-B in response to inflammatory cytokines in hRVECs was the subject of the present study.
n3-PUFAs, such as DHA 22:6n3 and EPA 20:5n3 , have long been recognized to modulate the inflammatory response and are widely applied clinically as an adjuvant immunosuppressant in the treatment of inflammatory disorders (reviewed in Refs. 24, 25) . Several studies in human umbilical vein endothelial cells (HUVECs), 26, 27 human saphenous vein endothelial cells, 28, 29 and glomerular endothelial cells 30 have demonstrated that n3 PUFAs and their products can effectively inhibit TNF␣-and IL-1␤-induced CAM expression. Retinal vascular endothelial cells have unusually high levels of PUFAs. 31 The response to fatty acids could be modified in retinal endothelial cells compared with endothelial cells from other organs. Indeed, we have previously demonstrated that hRVECs respond with much higher potency to n6 PUFA than do HUVECs. 32 Whether DHA 22:6n3 plays an anti-inflammatory role in the regulation of TNF␣-and IL-1␤-mediated induction of CAM expression in hRVECs similar to other endothelial cells has not been studied and represents the main focus of this study. Moreover, the effect of n3 PUFA on VEGF-induced CAM expression is not known and will be addressed in this study.
MATERIALS AND METHODS

Reagents
DMEM and F12 culture medium, antibiotics, fetal bovine serum, and trypsin were obtained from Invitrogen (Carlsbad, CA). Commonly used chemicals and reagents were from Sigma-Aldrich Chemical Co. (St. Louis, MO). TNF␣ and IL-1␤ were from R&D Systems (Minneapolis, MN). VEGF 165 was purchased from Calbiochem (San Diego, CA).
Cell Culture and Fatty Acid Treatment
Primary cultures of hRVECs obtained from at least three donors from the tissue provided by National Disease Research Interchange (Philadelphia, PA) were prepared and cultured, as previously described. 32 Passages 3 to 6 were used in the experiments. For experimental treatments, cells were transferred to serum-free medium for 18 to 24 hours before addition of the stimulatory agents. A dose-response curve was first established for each cytokine using the cells from each donor in the range of 0 to 10 ng/mL for TNF␣, 0 to 2 ng/mL for IL-1␤, and 0 to 50 ng/mL for VEGF 165 . The dose at which the maximum stimulation was achieved was used in all the consequent experiments.
Treatment of hRVECs with fatty acids was performed as follows. Fatty acid stocks were prepared by dissolving fatty acids (NuCheck Prep, Inc., Elysian, MN) in 100% ethanol, to a final concentration of 100 mM fatty acid. The fatty acid stock solutions were diluted in serum-free medium to reach concentrations of 100 M in the presence of 20 M of bovine serum albumin (BSA; charcoal-treated, solvent-extracted, fatty acid-free; Serologics Inc., Norcross, GA). The fatty acid-to-albumin molar ratio was maintained at 5:1. Cells were incubated for the times indicated in the Results section. The concentration of fatty acids used was within the physiological range and was confirmed by propidium iodide staining not to cause apoptosis (data not shown). Equivalent amounts of BSA alone were added to control plates. Palmitic 16:0 acid was chosen as a lipid control in this study based on the following considerations. The most abundant fatty acids in retinal endothelial cells are palmitic 16 31 and it does not have the proinflammatory properties of n6 PUFA.
32
SDS-PAGE and Western Blot Analysis
Cells were lysed in the lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1% Triton X-100, and 10% glycerol) with freshly added protease inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitors (1 mM Na 3 VO 4 , 100 M glycerophosphate, 10 mM NaF, and 1 mM Na 4 PP i ). Proteins were resolved by SDS-PAGE and transferred to nitrocellulose, immunoblotted using appropriate antibodies followed by secondary horseradish-peroxidase-conjugated antibody (Bio-Rad). Immunoreactive bands were visualized by enhanced chemiluminescence (ECL kit; GE Healthcare, Piscataway, NJ). Blots were quantitated by scanning densitometry using ImageJ software, ver. 1.29 (available by ftp at zippy.nimh.nih.gov/ or at http://rsb.info.nih. gov/nih-image; developed by Wayne Rasband, National Institutes of Health, Bethesda, MD).
Electrophoretic Mobility Gel Shift Assay
The double-stranded oligonucleotides containing the NF-B binding sequence derived from human vascular cell adhesion molecule (VCAM)-1 promoter were designed and synthesized as follows: 5ЈTGC-CCTGGGTTTCCCCTTGAAGGGATTTCCCTC-3Ј and 3Ј-GACCCAAAG-GGGAACTTCCCTAAAGGGAGGCGG-5Ј (NF-B binding domains are shown in bold). The oligonucleotides were annealed and labeled in the presence of [
32 P]dCTP with a random primer kit from Invitrogen, according to manufacturer's protocol. For binding reactions, nuclear extracts (6 g) were incubated in 25 L of total reaction volume with 32 P-labeled NF-B oligonucleotides for 20 minutes at room temperature. DNA-protein complexes were resolved on 6% nondenaturing polyacrylamide gels, and the bands were examined by autoradiography and quantitated using phosphorescent imaging (PhosphorImager; Molecular Dynamics, Sunnyvale, CA). Incubation of the nuclear extracts with excess cold NF-B oligonucleotides was used to confirm the specificity of binding activity.
Statistical Analysis
There are two variability levels involved in this study-experimental variability within the cells from the same donor and the interdonor variability. We statistically analyzed the experimental variability within the cells from the same donor and confirmed, but did not include in the analysis, the results from three different donors. Data are expressed as the mean Ϯ SD from one donor. ANOVA was used for comparing data obtained from independent samples. The Bonferroni procedure was used to control type I errors. Significance was established at P Ͻ 0.05.
RESULTS
Effect of TNF␣, IL-1␤, and VEGF 165 on Adhesion Molecule Expression in hRVECs
The inflammatory responsiveness of primary human retinal endothelial cells to the three proinflammatory cytokines (TNF␣, IL-1␤, and VEGF 165 ) known to be increased in diabetic eyes was first assessed with CAM expression as a measure. The doses of cytokines used in this study were selected based on the dose-response curves in the cells from each donor, as described in the Methods section (data not shown). TNF␣ (5 ng/mL) and IL-1␤ (1 ng/mL) acutely stimulated the expression of ICAM-1 and VCAM-1 (Fig. 1A) . Recombinant VEGF 165 (20 FIGURE 1. TNF␣, IL-1␤, and VEGF 165 induced expression of cell adhesion molecules in hRVECs. hRVECs were serum starved overnight and stimulated with 5 ng/mL TNF␣, 1 ng/mL IL-1␤ (A), or 20 ng/mL VEGF 165 (B) for different times, as indicated. Western blot exposure time in (B) was at least 30 times longer than that in (A), to illustrate the details of the VEGF response. For comparison of the actual potency of doses at which the maximum response is achieved for VEGF 165 (20 ng/mL for 6 hours) and IL-1␤ (1 ng/mL for 6 hours), the samples were loaded on the same gel and exposed for the same time as shown in (C). The induction of the adhesion molecules VCAM-1, ICAM-1, and Eselectin was assessed by immunoblot analyses. Equal amounts of protein were added to each lane, as confirmed by actin levels. Representative results from at least three independent experiments are shown.
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ng/mL), an important angiogenesis factor in diabetic retinopathy, also markedly induced ICAM-1 and VCAM-1 in hRVECs (Fig. 1B) . The VEGF 165 induction of ICAM-1 and VCAM-1 was time dependent, with VCAM-1 expression peaking at 24 hours and ICAM-1 expression persisting for up to 48 hours. There was no significant effect of cytokine stimulation on E-selectin expression at the time points checked (Fig. 1) . The Western blot analyses in Figure 1A and 1B are shown at different sensitivity levels to illustrate the details of the response to each cytokine; however, they do not provide information on the relative potency of IL-1␤, TNF␣, and VEGF. To compare the potency of angiogenesis factor VEGF 165 with classic inflammatory cytokines, such as IL-1␤, we treated hRVECs with the doses at which the maximum activation was achieved for each cytokine in the parallel plates and analyzed the samples on the same gel. As shown in Figure 1C , VEGF 165 has much weaker cytokine activity when compared with the inflammatory cytokine IL-1␤.
Effect of DHA 22:6n3 on TNF␣-, IL-1␤-, and VEGF 165 -Induced CAM Expression
Because DHA 22:6n3 is the most abundant retinal n3-PUFA, we evaluated the potential modulating effect of DHA 22:6n3 on the inflammatory response in retinal endothelial cells. Pretreatment of hRVECs with DHA 22:6n3 (100 M of BSA-bound DHA 22:6n3 for 24 hours) significantly inhibited IL-1␤-and TNF␣-induced VCAM-1 expression by approximately 40% and 50%, respectively (Figs. 2A, 2B ). In contrast, pretreatment with a lipid control (palmitate 16:0 ) did not exhibit a significant effect on cytokine-induced VCAM-1 expression (Figs. 2A, 2B) . Similarly, DHA 22:6n3 pretreatment inhibited VEGF 165 -induced VCAM-1 and ICAM-1 expression, whereas palmitic 16:0 acid pretreatment had no such effect (Fig. 2C) .
Role of NF-B in Regulating Cytokine-Induced Adhesion Molecule Expression in hRVECs
To investigate the role of NF-B in cytokine-induced adhesion molecule expression in hRVECs, a double-stranded DNA probe containing the specific NF-B binding site from human VCAM-1 promoter was used in electrophoretic mobility shift assay (EMSA) to study the activation and binding of NF-B to the promoters of adhesion molecules. As shown in Figures 3A, all three cytokines induced NF-B binding to the VCAM-1 promoter. VEGF 165 induced a delayed NF-B activation in the nucleus, with the NF-B induced shifts starting from 1 hour and peaking at 2 hours (Fig. 3A) . Moreover, Western blot analysis showed that two specific isoforms of the NF-B family, p65 and p50, accumulated in the nucleus after stimulation with IL-1␤ and TNF␣ (Fig. 3B) . Phosphorylation of p65 at Ser(536), necessary for optimal transactivation of NF-B, 33 was also observed in the nucleus of IL-1␤-and TNF␣-stimulated cells (Fig.  3B) . Likewise, VEGF 165 induced translocation of p50 and p65 into the nucleus (Fig. 3B) , although with no obvious p65 phosphorylation observed (data not shown).
Effect of DHA 22:6n3 Pretreatment on CytokineInduced NF-B Binding to the VCAM-1 Promoter
To address the molecular mechanism underlying the inhibitory effect of DHA 22:6n3 , we analyzed whether DHA 22 (Figs. 4B, 4C ). The decrease in NF-B binding was concomitant with a decrease in the nuclear level of p65 and p50 in DHA 22:6n3 -treated cells (Fig. 4D) , implying that DHA 22:6n3 decreases IL-1␤ induced nuclear trans- 
Effect of DHA 22:6n3 Pretreatment on I-B␣ Phosphorylation and Degradation
We next addressed the specific upstream step that DHA 22:6n3 acts on to inhibit cytokine-induced NF-B signaling, by evaluating the phosphorylation of one of the NF-B inhibitors (I-B␣) and its ubiquitin-mediated proteosome degradation. DHA 22:6n3 pretreatment attenuated IL-1␤-induced I-B␣ phosphorylation compared with the palmitate 16:0 -treated control (Figs. 5A , 5B). Attenuation of I-B␣ phosphorylation prevents I-B␣ degradation, thereby retaining NF-B in the inactive NF-B-I-B␣ complex in the cytosol (Figs. 5A , 5B). VEGF 165 , even at the highest dose used, was not as potent as IL-1␤ (Fig.  1C) . VEGF 165 -induced I-B␣ phosphorylation and degradation was below the sensitivity level of I-B␣ and phospho-I-B␣ antibodies used in this study (data not shown).
DISCUSSION
In chronic inflammatory conditions, endothelial cells actively recruit blood-borne leukocytes, such as monocytes and T lymphocytes to the underlying tissue, in response to the activation by cytokines and growth factors. This process is mediated by the increased expression of adhesion molecules on both leukocytes and endothelial cells. The early stages of diabetic retinopathy have been recognized as a chronic inflammatory disease. 1-3 Upregulation of inflammatory cytokines, especially TNF␣, 5-7 IL-1␤, 8, 9 and VEGF, 10 -12 along with their corresponding receptors have been well documented in the eyes of diabetic patients and in diabetic animal models. However, the effect of these principal cytokines on human retinal endothelial cell adhesion molecule expression, especially VCAM-1, a specific vascular inflammatory marker, has not been tested. This study demonstrated, for the first time that the inflammatory cytokines upregulated in the diabetic eye induce expression of adhesion molecules in cultures of human retinal endothelial cells. Our data further demonstrated the antiinflammatory effect of the principal n3-PUFA in the retina, DHA 22:6n3 , on cytokine-triggered inflammatory signaling.
NF-B, an essential nuclear factor in the regulation of inflammatory signaling, 21, 34 has been shown to be involved in the development of diabetic microvascular complications. 19, 22 Our data indicate that retinal endothelial cells contain the cognate receptors for TNF␣, IL-1␤, and VEGF 165 and that activation of these receptors leads to increased DNA binding activity of NF-B. The major NF-B isoforms activated by the inflammatory cytokines in hRVECs were p65 and p50, which normally form a p65/p50 heterodimer to mediate DNA binding. Previous studies have demonstrated increased accumulation of the p50, but not the p65, isoform of NF-B in nuclei of retinal endothelial cells from diabetic animals, 35 and only p65 has been shown to be increased in retinal pericyte nuclei but not in endothelial cells from patients with diabetic retinopathy patients and/or in cells from STZ-induced diabetic rats. 23 The apparent differences could come from the different systems used. The results in our study of cultured human retinal endothelial cells emphasize that both p65 and p50 are important DNA-binding transcription factors activated by proinflammatory cytokines to mediate VCAM-1 and ICAM-1 expression.
Our data agree with those in other reports showing that ICAM-1 is a critical adhesion molecule elevated in diabetic retinas and that VEGF 165 is a proinflammatory cytokine capable of inducing its expression. 19, 20 A significant finding in this There was a very minor, if any, increase in E-selectin expression after 6 and 24 hours of cytokine stimulation in hRVECs. Studies in endothelial cells from other organs have demonstrated E-selectin activation after cytokine stimulation. The apparent discrepancy could be explained by organ specificity. A recent study of human microvascular endothelial cells from different organs demonstrated organ-specific CAM expression and activation patterns. 36 Although retinal endothelial cells were not analyzed in that study, brain microvascular endothelial cells, which are very close to retinal endothelial cells in structure and fatty acid composition, had the lowest E-selectin response to cytokine activation. n3-PUFAs have long been recognized to modulate inflammatory responses and are widely applied clinically as an adjuvant immunosuppressant in the treatment of various inflammatory disorders. 24, 25 Numerous studies have shown that treatment with n3-PUFAs inhibits adhesion molecule and cytokine expression induced by inflammatory agents. 24,26 -30 Our study of human retinal endothelial cells strongly supports an important role for DHA 22:6n3 as an anti-inflammatory agent in ameliorating endothelial cell response to cytokines in these primary target cells. The dose of DHA 22:6n3 used in this study was within a normal physiological range. Higher doses of DHA 22:6n3 may have a more prominent effect on NF-B signaling; however, we chose to use the low dose because high concentrations of fatty acids in general could have adverse effects on the cells and may be proapoptotic. Moreover, concentrations higher than the levels achievable in vivo would not provide information relevant to diabetic retinopathy. The fact that DHA 22:6n3 , even at this low dose, attenuates the effect of such potent cytokines as TNF␣ and IL-1␤ by as much as 25% to 50% is of great clinical importance.
The specific mechanisms underlying the anti-inflammatory effect of n3 PUFA have been intensively sought for decades. Several possible mechanisms have been suggested, including the displacement of the major substrate for the synthesis of proinflammatory eicosanoids, arachidonic acid 20:4n6 , from sn-2 position in membrane phospholipids 37 ; direct activation of the nuclear receptors, such as peroxisome proliferators-activated receptors (PPARs) 38 -44 ; or modification of specific plasma membrane domains called lipid rafts or caveolae. 45, 46 All these pathways are likely to play a role in DHA 22:6n3 effects in hRVECs.
In our study, DHA 22:6n3 not only attenuated the nuclear translocation and DNA binding of p50/p65 NF-B isoforms, but also inhibited the upstream I-B␣ phosphorylation and degradation (Fig. 6 ). This implies that DHA 22:6n3 acts at least upstream of I-B␣ to inhibit inflammatory signaling in hRVECs. The more specific upstream steps where DHA 22:6n3 acts are under investigation. However, modification of lipid composition of caveolae-lipid rafts and caveolae-lipid raft signaling components, similar to that observed in T cells, 45, 46 represents a very plausible possibility (Fig. 6) .
In summary, our data demonstrate that three major inflammatory cytokines, known to be upregulated in diabetic eyes-TNF␣, IL-1␤, and VEGF 165 -induce VCAM-1 and ICAM-1 expression through activating the NF-B pathway in primary human retinal endothelial cells. DHA 22:6n3 plays a central role in antagonizing cytokine-induced adhesion molecule expression by attenuating NF-B signaling in the early steps in inflammation in hRVECs. Our data suggest that DHA 22:6n3 is a principal anti-inflammatory agent in the face of activated cytokine production in the diabetic retina.
